25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Imexpharm Corp
Buy, Hold or Sell?

Let's analyze Imexpharm together

I guess you are interested in Imexpharm Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Imexpharm Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Imexpharm Corp

I send you an email if I find something interesting about Imexpharm Corp.

1. Quick Overview

1.1. Quick analysis of Imexpharm (30 sec.)










1.2. What can you expect buying and holding a share of Imexpharm? (30 sec.)

How much money do you get?

How much money do you get?
₫ 0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₫ 13,490.54
Expected worth in 1 year
₫ 14,368.01
How sure are you?
77.8%

+ What do you gain per year?

Total Gains per Share
₫ 877.48
Return On Investment
2.0%

For what price can you sell your share?

Current Price per Share
₫ 43,700.00
Expected price per share
₫ 34,259 - ₫ 46,600
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Imexpharm (5 min.)




Live pricePrice per Share (EOD)
₫ 43,700.00

2.2. Growth of Imexpharm (5 min.)




Is Imexpharm growing?

Current yearPrevious yearGrowGrow %
How rich?$83.1m$76.3m$6.8m8.2%

How much money is Imexpharm making?

Current yearPrevious yearGrowGrow %
Making money$2.6m$2.8m-$119.3k-4.4%
Net Profit Margin13.0%15.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Imexpharm (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Imexpharm?

Welcome investor! Imexpharm's management wants to use your money to grow the business. In return you get a share of Imexpharm.

First you should know what it really means to hold a share of Imexpharm. And how you can make/lose money.

Speculation

The Price per Share of Imexpharm is ₫ 43,700. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Imexpharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Imexpharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₫ 13,490.54. Based on the TTM, the Book Value Change Per Share is ₫ 219.37 per quarter. Based on the YOY, the Book Value Change Per Share is ₫ 279.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₫ 0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Imexpharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.020.0%0.020.0%0.020.0%0.020.0%0.020.0%
Usd Book Value Change Per Share-0.020.0%0.010.0%0.010.0%0.060.0%0.060.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.020.0%0.010.0%0.010.0%0.060.0%0.060.0%
Usd Price Per Share3.01-2.69-2.30-2.48-2.48-
Price to Earnings Ratio43.98-38.59-37.11-39.11-39.11-
Price-to-Total Gains Ratio-168.47-68.28-20.93-40.23-40.23-
Price to Book Ratio5.58-4.97-4.66-4.86-4.86-
Price-to-Total Gains Ratio-168.47-68.28-20.93-40.23-40.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.748
Number of shares572
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.06
Usd Total Gains Per Share0.010.06
Gains per Quarter (572 shares)5.0234.30
Gains per Year (572 shares)20.08137.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1020100137127
2040300274264
3060500412401
4080700549538
50100900686675
601201100823812
701411300960949
80161150010971086
90181170012351223
100201190013721360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%7.02.00.077.8%7.02.00.077.8%7.02.00.077.8%7.02.00.077.8%
Dividend per Share0.00.04.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share3.01.00.075.0%7.02.00.077.8%7.02.00.077.8%7.02.00.077.8%7.02.00.077.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Imexpharm Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---446.957219.369-304%279.861-260%1498.948-130%1498.948-130%
Book Value Per Share--13490.53613507.2820%12394.007+9%12788.752+5%12788.752+5%
Current Ratio--3.1813.468-8%2.750+16%3.082+3%3.082+3%
Debt To Asset Ratio--0.1710.156+10%0.183-7%0.168+2%0.168+2%
Debt To Equity Ratio--0.2060.185+11%0.225-9%0.203+1%0.203+1%
Dividend Per Share----0%-0%-0%-0%
Eps--428.049438.120-2%395.865+8%404.289+6%404.289+6%
Free Cash Flow Per Share--256.81127.701+827%13.853+1754%80.098+221%80.098+221%
Free Cash Flow To Equity Per Share--256.811-135.640+153%91.551+181%42.034+511%42.034+511%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap6730192950400.000-72%11596877436419.78310341704120817.984+12%8865142879216.188+31%9554547033483.650+21%9554547033483.650+21%
Net Profit Margin--0.1270.130-2%0.150-15%0.139-8%0.139-8%
Operating Margin---0.047-100%0.108-100%0.069-100%0.069-100%
Operating Ratio--1.4461.460-1%1.362+6%1.415+2%1.415+2%
Pb Ratio3.239-72%5.5824.974+12%4.658+20%4.856+15%4.856+15%
Pe Ratio25.523-72%43.97938.594+14%37.113+18%39.109+12%39.109+12%
Price Per Share43700.000-72%75300.00267150.002+12%57562.502+31%62038.891+21%62038.891+21%
Price To Free Cash Flow Ratio42.541-72%73.303-3.720+105%3.720+1870%2.980+2360%2.980+2360%
Price To Total Gains Ratio-97.772+42%-168.47368.281-347%20.934-905%40.226-519%40.226-519%
Quick Ratio--1.1021.097+0%1.188-7%1.138-3%1.138-3%
Return On Assets--0.0260.027-4%0.030-12%0.028-6%0.028-6%
Return On Equity--0.0320.032-2%0.037-14%0.034-6%0.034-6%
Total Gains Per Share---446.957219.369-304%279.861-260%1498.948-130%1498.948-130%
Usd Book Value--83106552.91983209714.7820%76351543.109+9%78783314.616+5%78783314.616+5%
Usd Book Value Change Per Share---0.0180.009-304%0.011-260%0.060-130%0.060-130%
Usd Book Value Per Share--0.5400.5400%0.496+9%0.512+5%0.512+5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0170.018-2%0.016+8%0.016+6%0.016+6%
Usd Free Cash Flow--1582046.659170645.505+827%85342.094+1754%493429.584+221%493429.584+221%
Usd Free Cash Flow Per Share--0.0100.001+827%0.001+1754%0.003+221%0.003+221%
Usd Free Cash Flow To Equity Per Share--0.010-0.005+153%0.004+181%0.002+511%0.002+511%
Usd Market Cap269207718.016-72%463875097.457413668164.833+12%354605715.169+31%382181881.339+21%382181881.339+21%
Usd Price Per Share1.748-72%3.0122.686+12%2.303+31%2.482+21%2.482+21%
Usd Profit--2636936.9972698979.588-2%2818286.138-6%2659283.074-1%2659283.074-1%
Usd Revenue--20688845.97820833960.024-1%18939731.210+9%19252536.375+7%19252536.375+7%
Usd Total Gains Per Share---0.0180.009-304%0.011-260%0.060-130%0.060-130%
 EOD+5 -3MRQTTM+10 -23YOY+17 -165Y+15 -1810Y+15 -18

3.3 Fundamental Score

Let's check the fundamental score of Imexpharm Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1525.523
Price to Book Ratio (EOD)Between0-13.239
Net Profit Margin (MRQ)Greater than00.127
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.102
Current Ratio (MRQ)Greater than13.181
Debt to Asset Ratio (MRQ)Less than10.171
Debt to Equity Ratio (MRQ)Less than10.206
Return on Equity (MRQ)Greater than0.150.032
Return on Assets (MRQ)Greater than0.050.026
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Imexpharm Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.826
Ma 20Greater thanMa 5043,377.500
Ma 50Greater thanMa 10046,229.000
Ma 100Greater thanMa 20050,239.804
OpenGreater thanClose44,000.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Imexpharm Corp

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company's products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-histamines, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals. It is also involved in the import and export of medical equipment and supplies, chemicals, materials for medicine manufacturing and packaging, and chemicals used for sterilization or disinfection in humans. The company was founded in 1977 and is headquartered in Cao Lanh, Vietnam.

Fundamental data was last updated by Penke on 2024-11-13 16:33:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Imexpharm earns for each ₫1 of revenue.

  • Above 10% is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 12.7% means that ₫0.13 for each ₫1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Imexpharm Corp:

  • The MRQ is 12.7%. The company is making a huge profit. +2
  • The TTM is 13.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.7%TTM13.0%-0.3%
TTM13.0%YOY15.0%-2.0%
TTM13.0%5Y13.9%-0.9%
5Y13.9%10Y13.9%0.0%
4.3.1.2. Return on Assets

Shows how efficient Imexpharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.6% Return on Assets means that Imexpharm generated ₫0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Imexpharm Corp:

  • The MRQ is 2.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.6%TTM2.7%-0.1%
TTM2.7%YOY3.0%-0.3%
TTM2.7%5Y2.8%-0.1%
5Y2.8%10Y2.8%0.0%
4.3.1.3. Return on Equity

Shows how efficient Imexpharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.2% Return on Equity means Imexpharm generated ₫0.03 for each ₫1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Imexpharm Corp:

  • The MRQ is 3.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.2%TTM3.2%-0.1%
TTM3.2%YOY3.7%-0.4%
TTM3.2%5Y3.4%-0.1%
5Y3.4%10Y3.4%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Imexpharm Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Imexpharm is operating .

  • Measures how much profit Imexpharm makes for each ₫1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₫0.00  for each ₫1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Imexpharm Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.7%-4.7%
TTM4.7%YOY10.8%-6.1%
TTM4.7%5Y6.9%-2.2%
5Y6.9%10Y6.9%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Imexpharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.45 means that the operating costs are ₫1.45 for each ₫1 in net sales.

Let's take a look of the Operating Ratio trends of Imexpharm Corp:

  • The MRQ is 1.446. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.460. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.446TTM1.460-0.014
TTM1.460YOY1.362+0.098
TTM1.4605Y1.415+0.045
5Y1.41510Y1.4150.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Imexpharm Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Imexpharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.18 means the company has ₫3.18 in assets for each ₫1 in short-term debts.

Let's take a look of the Current Ratio trends of Imexpharm Corp:

  • The MRQ is 3.181. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.468. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.181TTM3.468-0.288
TTM3.468YOY2.750+0.718
TTM3.4685Y3.082+0.387
5Y3.08210Y3.0820.000
4.4.3.2. Quick Ratio

Measures if Imexpharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.10 means the company can pay off ₫1.10 for each ₫1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Imexpharm Corp:

  • The MRQ is 1.102. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.097. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.102TTM1.097+0.005
TTM1.097YOY1.188-0.091
TTM1.0975Y1.138-0.041
5Y1.13810Y1.1380.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Imexpharm Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Imexpharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Imexpharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.17 means that Imexpharm assets are financed with 17.1% credit (debt) and the remaining percentage (100% - 17.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Imexpharm Corp:

  • The MRQ is 0.171. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.156. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.156+0.015
TTM0.156YOY0.183-0.027
TTM0.1565Y0.168-0.012
5Y0.16810Y0.1680.000
4.5.4.2. Debt to Equity Ratio

Measures if Imexpharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 20.6% means that company has ₫0.21 debt for each ₫1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Imexpharm Corp:

  • The MRQ is 0.206. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.185. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.206TTM0.185+0.020
TTM0.185YOY0.225-0.039
TTM0.1855Y0.203-0.017
5Y0.20310Y0.2030.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₫1 in earnings Imexpharm generates.

  • Above 15 is considered overpriced but always compare Imexpharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 43.98 means the investor is paying ₫43.98 for every ₫1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Imexpharm Corp:

  • The EOD is 25.523. Based on the earnings, the company is overpriced. -1
  • The MRQ is 43.979. Based on the earnings, the company is overpriced. -1
  • The TTM is 38.594. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD25.523MRQ43.979-18.456
MRQ43.979TTM38.594+5.384
TTM38.594YOY37.113+1.481
TTM38.5945Y39.109-0.514
5Y39.10910Y39.1090.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Imexpharm Corp:

  • The EOD is 42.541. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 73.303. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -3.720. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD42.541MRQ73.303-30.762
MRQ73.303TTM-3.720+77.023
TTM-3.720YOY3.720-7.440
TTM-3.7205Y2.980-6.700
5Y2.98010Y2.9800.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Imexpharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 5.58 means the investor is paying ₫5.58 for each ₫1 in book value.

Let's take a look of the Price to Book Ratio trends of Imexpharm Corp:

  • The EOD is 3.239. Based on the equity, the company is fair priced.
  • The MRQ is 5.582. Based on the equity, the company is overpriced. -1
  • The TTM is 4.974. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.239MRQ5.582-2.342
MRQ5.582TTM4.974+0.607
TTM4.974YOY4.658+0.316
TTM4.9745Y4.856+0.118
5Y4.85610Y4.8560.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in VND. All numbers in thousands.

Summary
Total Assets2,504,991,924
Total Liabilities427,328,102
Total Stockholder Equity2,077,663,823
 As reported
Total Liabilities 427,328,102
Total Stockholder Equity+ 2,077,663,823
Total Assets = 2,504,991,924

Assets

Total Assets2,504,991,924
Total Current Assets1,359,274,707
Long-term Assets1,145,717,218
Total Current Assets
Cash And Cash Equivalents 127,521,203
Short-term Investments 132,000,000
Net Receivables 338,987,224
Inventory 713,157,927
Total Current Assets  (as reported)1,359,274,707
Total Current Assets  (calculated)1,311,666,354
+/- 47,608,353
Long-term Assets
Property Plant Equipment 923,187,113
Intangible Assets 106,120,807
Long-term Assets  (as reported)1,145,717,218
Long-term Assets  (calculated)1,029,307,920
+/- 116,409,298

Liabilities & Shareholders' Equity

Total Current Liabilities427,328,102
Long-term Liabilities0
Total Stockholder Equity2,077,663,823
Total Current Liabilities
Short Long Term Debt 96,413,185
Accounts payable 71,751,551
Total Current Liabilities  (as reported)427,328,102
Total Current Liabilities  (calculated)168,164,736
+/- 259,163,365
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings 433,180,217
Total Stockholder Equity (as reported)2,077,663,823
Total Stockholder Equity (calculated)433,180,217
+/- 1,644,483,606
Other
Capital Stock700,384,490
Common Stock Shares Outstanding 77,005
Net Invested Capital 2,174,077,008
Net Working Capital 931,946,605
Property Plant and Equipment Gross 1,560,670,408



6.2. Balance Sheets Structured

Currency in VND. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-30
> Total Assets 
2,097,230,925
2,189,034,194
2,276,943,568
2,366,362,303
2,522,727,591
2,486,758,656
2,392,615,157
2,473,346,446
2,504,991,924
2,504,991,9242,473,346,4462,392,615,1572,486,758,6562,522,727,5912,366,362,3032,276,943,5682,189,034,1942,097,230,925
   > Total Current Assets 
936,385,844
1,010,922,381
1,103,552,902
1,192,751,311
1,337,582,163
1,303,059,858
1,207,134,868
1,316,561,492
1,359,274,707
1,359,274,7071,316,561,4921,207,134,8681,303,059,8581,337,582,1631,192,751,3111,103,552,9021,010,922,381936,385,844
       Cash And Cash Equivalents 
67,242,993
64,843,710
178,845,070
58,707,521
66,785,436
97,983,080
106,200,569
108,744,980
127,521,203
127,521,203108,744,980106,200,56997,983,08066,785,43658,707,521178,845,07064,843,71067,242,993
       Short-term Investments 
176,300,000
251,300,000
211,300,000
293,000,000
303,000,000
103,000,000
93,000,000
132,000,000
132,000,000
132,000,000132,000,00093,000,000103,000,000303,000,000293,000,000211,300,000251,300,000176,300,000
       Net Receivables 
184,300,743
205,957,905
231,177,991
248,465,363
255,929,023
276,411,959
256,814,121
309,563,990
338,987,224
338,987,224309,563,990256,814,121276,411,959255,929,023248,465,363231,177,991205,957,905184,300,743
       Inventory 
424,349,426
400,305,829
435,841,477
529,532,272
657,788,772
771,009,670
699,445,524
706,087,571
713,157,927
713,157,927706,087,571699,445,524771,009,670657,788,772529,532,272435,841,477400,305,829424,349,426
   > Long-term Assets 
1,160,845,082
1,178,111,813
1,173,390,666
1,173,610,992
1,185,145,428
1,183,698,798
1,185,480,289
1,156,784,954
1,145,717,218
1,145,717,2181,156,784,9541,185,480,2891,183,698,7981,185,145,4281,173,610,9921,173,390,6661,178,111,8131,160,845,082
       Property Plant Equipment 
0
1,001,005,855
996,450,354
993,490,153
1,003,330,307
924,938,752
945,503,947
928,510,763
923,187,113
923,187,113928,510,763945,503,947924,938,7521,003,330,307993,490,153996,450,3541,001,005,8550
       Intangible Assets 
73,094,796
73,058,605
72,978,380
72,738,682
74,781,312
74,577,121
104,447,359
102,005,965
106,120,807
106,120,807102,005,965104,447,35974,577,12174,781,31272,738,68272,978,38073,058,60573,094,796
       Other Assets 
0
0
32,672,358
36,092,583
35,752,254
112,901,369
0
0
0
000112,901,36935,752,25436,092,58332,672,35800
> Total Liabilities 
327,110,926
363,124,629
382,496,675
394,089,108
580,202,933
474,529,137
308,036,214
326,847,254
427,328,102
427,328,102326,847,254308,036,214474,529,137580,202,933394,089,108382,496,675363,124,629327,110,926
   > Total Current Liabilities 
327,110,926
363,124,629
382,496,675
394,089,108
580,202,933
474,529,137
308,036,214
326,847,254
427,328,102
427,328,102326,847,254308,036,214474,529,137580,202,933394,089,108382,496,675363,124,629327,110,926
       Short Long Term Debt 
93,600,000
131,029,214
94,980,000
100,667,951
180,317,558
79,649,607
49,421,829
118,579,634
96,413,185
96,413,185118,579,63449,421,82979,649,607180,317,558100,667,95194,980,000131,029,21493,600,000
       Accounts payable 
61,597,266
61,684,834
85,922,688
112,162,840
112,149,935
95,864,021
70,504,682
77,109,107
71,751,551
71,751,55177,109,10770,504,68295,864,021112,149,935112,162,84085,922,68861,684,83461,597,266
       Other Current Liabilities 
0
0
0
66,626,317
145,632,109
189,204,364
0
0
0
000189,204,364145,632,10966,626,317000
   > Long-term Liabilities 000000000
> Total Stockholder Equity
1,770,119,999
1,825,909,565
1,894,446,893
1,972,273,194
1,942,524,658
2,012,229,519
2,084,578,944
2,146,499,192
2,077,663,823
2,077,663,8232,146,499,1922,084,578,9442,012,229,5191,942,524,6581,972,273,1941,894,446,8931,825,909,5651,770,119,999
   Common Stock
0
0
667,053,700
667,053,700
667,053,700
667,053,700
0
0
0
000667,053,700667,053,700667,053,700667,053,70000
   Retained Earnings 
109,397,388
174,533,297
264,645,163
795,789,057
766,040,521
835,745,382
440,095,337
502,015,586
433,180,217
433,180,217502,015,586440,095,337835,745,382766,040,521795,789,057264,645,163174,533,297109,397,388
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
0
0
2,420,789
2,420,789
2,420,789
2,420,789
0
0
0
0002,420,7892,420,7892,420,7892,420,78900



6.3. Balance Sheets

Currency in VND. All numbers in thousands.




6.4. Cash Flows

Currency in VND. All numbers in thousands.




6.5. Income Statements

Currency in VND. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in VND. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,994,036,910
Cost of Revenue-1,183,501,179
Gross Profit810,535,731810,535,731
 
Operating Income (+$)
Gross Profit810,535,731
Operating Expense-1,612,989,957
Operating Income381,046,953-802,454,226
 
Operating Expense (+$)
Research Development0
Selling General Administrative235,504,544
Selling And Marketing Expenses0
Operating Expense1,612,989,957235,504,544
 
Net Interest Income (+$)
Interest Income16,885,258
Interest Expense-6,036,185
Other Finance Cost-23,093,358
Net Interest Income-12,244,285
 
Pretax Income (+$)
Operating Income381,046,953
Net Interest Income-12,244,285
Other Non-Operating Income Expenses0
Income Before Tax (EBT)377,272,934381,046,953
EBIT - interestExpense = -6,036,185
299,556,006
305,592,191
Interest Expense6,036,185
Earnings Before Interest and Taxes (EBIT)0383,309,119
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax377,272,934
Tax Provision-77,716,929
Net Income From Continuing Ops299,556,006299,556,006
Net Income299,556,006
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net012,244,285
 

Technical Analysis of Imexpharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Imexpharm. The general trend of Imexpharm is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Imexpharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Imexpharm Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 46,000 < 46,000 < 46,600.

The bearish price targets are: 39,300 > 38,500 > 34,259.

Tweet this
Imexpharm Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Imexpharm Corp. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Imexpharm Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Imexpharm Corp. The current macd is -1,227.18703747.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Imexpharm price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Imexpharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Imexpharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Imexpharm Corp Daily Moving Average Convergence/Divergence (MACD) ChartImexpharm Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Imexpharm Corp. The current adx is 20.41.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Imexpharm shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Imexpharm Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Imexpharm Corp. The current sar is 41,200.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Imexpharm Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Imexpharm Corp. The current rsi is 46.83. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Imexpharm Corp Daily Relative Strength Index (RSI) ChartImexpharm Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Imexpharm Corp. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Imexpharm price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Imexpharm Corp Daily Stochastic Oscillator ChartImexpharm Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Imexpharm Corp. The current cci is 43.15.

Imexpharm Corp Daily Commodity Channel Index (CCI) ChartImexpharm Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Imexpharm Corp. The current cmo is 11.07.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Imexpharm Corp Daily Chande Momentum Oscillator (CMO) ChartImexpharm Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Imexpharm Corp. The current willr is -35.8974359.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Imexpharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Imexpharm Corp Daily Williams %R ChartImexpharm Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Imexpharm Corp.

Imexpharm Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Imexpharm Corp. The current atr is 1,280.

Imexpharm Corp Daily Average True Range (ATR) ChartImexpharm Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Imexpharm Corp. The current obv is 3,290,142.

Imexpharm Corp Daily On-Balance Volume (OBV) ChartImexpharm Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Imexpharm Corp. The current mfi is 30.53.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Imexpharm Corp Daily Money Flow Index (MFI) ChartImexpharm Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Imexpharm Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Imexpharm Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Imexpharm Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.826
Ma 20Greater thanMa 5043,377.500
Ma 50Greater thanMa 10046,229.000
Ma 100Greater thanMa 20050,239.804
OpenGreater thanClose44,000.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Imexpharm with someone you think should read this too:
  • Are you bullish or bearish on Imexpharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Imexpharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Imexpharm Corp

I send you an email if I find something interesting about Imexpharm Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Imexpharm Corp.

Receive notifications about Imexpharm Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.